Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs Etoposide/Cisplatin as First-Line Therapy for Patients With Extensive Disease Small Cell Lung Cancer

NCT00006374 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00006374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs Etoposide/Cisplatin as First-Line Therapy for Patients With Extensive Disease Small Cell Lung Cancer
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
October 31, 1999
Completion date
June 30, 2001
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer